Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade war continues to escalate with new tariffs.

Shares of Pfizer Inc. PFE shed 3.49% to $21.84 Tuesday, on what proved to be an all-around poor trading session for the stock ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of $34.00. The company’s shares closed yesterday at $22.63.

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

Shares of drugmakers fell on Wednesday after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. Trump on Tuesday said his administration ...

Shares of some drugmakers rose on Wednesday after President Donald Trump said he would pause steep tariff rates on dozens of countries, temporarily easing fears about the impact of potential ...